Case Report: Reversal of Integrase Inhibitor- A nd Tenofovir Alafenamide-Related Weight Gain after Switching Back to Efavirenz/Emtricitabine/Tenofovir DF

Abstract

We report a case of substantial weight gain in a virologically suppressed patient with HIV after changing his antiretroviral therapy from efavirenz/emtricitabine/tenofovir DF to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide with subsequent rapid weight loss upon switching back. The role of antiretrovirals in weight gain and loss and patient- A nd HIV-specific factors are discussed.